114. SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE 2)
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.